Answers are grounded in this paper and cite their sources.
Alterations of epigenetic marks have an important role in myeloid malignancies. 1 Mutations have been found in several epigenetic regulators including ASXL1, DNMT3A, EZH2, IDH1/2 and TET2. 2 , 3 DNMT3A, IDH1/2 and TET2 are involved in the regulation of DNA methylation. EZH2 belongs to a complex of proteins called ‘polycomb repressor complex 2’ (PRC2). 4 ASXL1 is a regulator of PRC1, the other polycomb complex. Several other proteins belong to the two polycomb complexes; although alterations of ASXL1 5 and EZH2 6 , 7 are probably prominent in myeloid diseases, we suspected that these other PRC components might also be involved in some cases.
No takes yet. Share an insight, caveat, or question.
Brecqueville et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: